Search

Your search keyword '"Szymonifka, Jackie"' showing total 274 results
Start Over Author "Szymonifka, Jackie" Publication Year Range Last 10 years
274 results on '"Szymonifka, Jackie"'

2. Validation of the Hip Disability and Osteoarthritis Outcome Score and Knee Injury and Osteoarthritis Outcome Score Pain and Function Subscales for Use in Total Hip Replacement and Total Knee Replacement Clinical Trials

Author

Goodman, Susan M., Mehta, Bella Y., Mandl, Lisa A., Szymonifka, Jackie D., Finik, Jackie, Figgie, Mark P., Navarro-Millán, Iris Y., Bostrom, Mathias P., Parks, Michael L., Padgett, Douglas E., McLawhorn, Alexander S., Antao, Vinicius C., Yates, Adolph J., Springer, Bryan D., Lyman, Stephen L., and Singh, Jasvinder A.

Published
2020
Full Text
View/download PDF

4. Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: The BIOCRT study

Author

Truong, Quynh A, Januzzi, James L, Szymonifka, Jackie, Thai, Wai-ee, Wai, Bryan, Lavender, Zachary, Sharma, Umesh, Sandoval, Ryan M, Grunau, Zachary S, Basnet, Sandeep, Babatunde, Adefolakemi, Ajijola, Olujimi A, Min, James K, and Singh, Jagmeet P

Subjects
Clinical Research, Cardiovascular, Heart Disease, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, 4.2 Evaluation of markers and technologies, Aged, Aged, 80 and over, Biomarkers, Blood Specimen Collection, Cardiac Resynchronization Therapy, Coronary Sinus, Female, Follow-Up Studies, Galectin 3, Heart Failure, Humans, Male, Middle Aged, Natriuretic Peptide, Brain, Peptide Fragments, Predictive Value of Tests, Prospective Studies, Risk Assessment, Severity of Illness Index, Survival Rate, Treatment Outcome, Veins, Biomarker, Coronary sinus, Galectin-3, Soluble 512, Cardiac resynchronization therapy, Soluble ST2, Biomedical Engineering, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology
Abstract

BackgroundA significant minority of patients receiving cardiac resynchronization therapy (CRT) remain nonresponsive to this intervention.ObjectiveThis study aimed to determine whether coronary sinus (CS) or baseline peripheral venous (PV) levels of established and emerging heart failure (HF) biomarkers are predictive of CRT outcomes.MethodsIn 73 patients (aged 68 ± 12 years; 83% men; ejection fraction 27% ± 7%) with CS and PV blood samples drawn simultaneously at the time of CRT device implantation, we measured amino-terminal pro-B-type natriuretic peptide (NT-proBNP), galectin-3 (gal-3), and soluble ST2 (sST2) levels. NT-proBNP concentrations >2000 pg/mL, gal-3 concentrations >25.9 ng/mL, and sST2 concentrations >35 ng/mL were considered positive on the basis of established PV cut points for identifying "high-risk" individuals with HF. CRT response was adjudicated by the HF Clinical Composite Score. A major adverse cardiovascular event (MACE) was defined as the composite end point of death, cardiac transplant, left ventricular assist device, and HF hospitalization at 2 years.ResultsNT-proBNP concentrations were 20% higher in the CS than in the periphery, while gal-3 and sST2 concentrations were 10% higher in the periphery than in the CS (all P < .001). There were 45% CRT nonresponders at 6 months and 16 (22%) patients with MACE. Triple-positive CS values yielded the highest specificity of 95% for predicting CRT nonresponse. Consistently, CS strategies identified patients at higher risk of developing MACE, with >11-fold adjusted increase for triple-positive CS patients compared to triple-negative patients (all P ≤ .04). PV strategies were not predictive of MACE.ConclusionOur findings suggest that CS sampling of HF biomarkers may be better than PV sampling for predicting CRT outcomes. Larger studies are needed to confirm our findings.

Published
2014

15. Supplementary Table 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Author

Heuck, Christoph J., primary, Szymonifka, Jackie, primary, Hansen, Emily, primary, Shaughnessy, John D., primary, Usmani, Saad Z., primary, van Rhee, Frits, primary, Anaissie, Elias, primary, Nair, Bijay, primary, Waheed, Sarah, primary, Alsayed, Yazan, primary, Petty, Nathan, primary, Bailey, Clyde, primary, Epstein, Joshua, primary, Hoering, Antje, primary, Crowley, John, primary, and Barlogie, Bart, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Author

Heuck, Christoph J., primary, Szymonifka, Jackie, primary, Hansen, Emily, primary, Shaughnessy, John D., primary, Usmani, Saad Z., primary, van Rhee, Frits, primary, Anaissie, Elias, primary, Nair, Bijay, primary, Waheed, Sarah, primary, Alsayed, Yazan, primary, Petty, Nathan, primary, Bailey, Clyde, primary, Epstein, Joshua, primary, Hoering, Antje, primary, Crowley, John, primary, and Barlogie, Bart, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 2 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Author

Heuck, Christoph J., primary, Szymonifka, Jackie, primary, Hansen, Emily, primary, Shaughnessy, John D., primary, Usmani, Saad Z., primary, van Rhee, Frits, primary, Anaissie, Elias, primary, Nair, Bijay, primary, Waheed, Sarah, primary, Alsayed, Yazan, primary, Petty, Nathan, primary, Bailey, Clyde, primary, Epstein, Joshua, primary, Hoering, Antje, primary, Crowley, John, primary, and Barlogie, Bart, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 3 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Author

Heuck, Christoph J., primary, Szymonifka, Jackie, primary, Hansen, Emily, primary, Shaughnessy, John D., primary, Usmani, Saad Z., primary, van Rhee, Frits, primary, Anaissie, Elias, primary, Nair, Bijay, primary, Waheed, Sarah, primary, Alsayed, Yazan, primary, Petty, Nathan, primary, Bailey, Clyde, primary, Epstein, Joshua, primary, Hoering, Antje, primary, Crowley, John, primary, and Barlogie, Bart, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure Legend from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Author

Heuck, Christoph J., primary, Szymonifka, Jackie, primary, Hansen, Emily, primary, Shaughnessy, John D., primary, Usmani, Saad Z., primary, van Rhee, Frits, primary, Anaissie, Elias, primary, Nair, Bijay, primary, Waheed, Sarah, primary, Alsayed, Yazan, primary, Petty, Nathan, primary, Bailey, Clyde, primary, Epstein, Joshua, primary, Hoering, Antje, primary, Crowley, John, primary, and Barlogie, Bart, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure 4 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Author

Heuck, Christoph J., primary, Szymonifka, Jackie, primary, Hansen, Emily, primary, Shaughnessy, John D., primary, Usmani, Saad Z., primary, van Rhee, Frits, primary, Anaissie, Elias, primary, Nair, Bijay, primary, Waheed, Sarah, primary, Alsayed, Yazan, primary, Petty, Nathan, primary, Bailey, Clyde, primary, Epstein, Joshua, primary, Hoering, Antje, primary, Crowley, John, primary, and Barlogie, Bart, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure 5 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Author

Heuck, Christoph J., primary, Szymonifka, Jackie, primary, Hansen, Emily, primary, Shaughnessy, John D., primary, Usmani, Saad Z., primary, van Rhee, Frits, primary, Anaissie, Elias, primary, Nair, Bijay, primary, Waheed, Sarah, primary, Alsayed, Yazan, primary, Petty, Nathan, primary, Bailey, Clyde, primary, Epstein, Joshua, primary, Hoering, Antje, primary, Crowley, John, primary, and Barlogie, Bart, primary

Published
2023
Full Text
View/download PDF

34. Spatial environmental factors predict cardiovascular and all-cause mortality: Results of the SPACE study

Author

Hadley, Michael B., primary, Nalini, Mahdi, additional, Adhikari, Samrachana, additional, Szymonifka, Jackie, additional, Etemadi, Arash, additional, Kamangar, Farin, additional, Khoshnia, Masoud, additional, McChane, Tyler, additional, Pourshams, Akram, additional, Poustchi, Hossein, additional, Sepanlou, Sadaf G., additional, Abnet, Christian, additional, Freedman, Neal D., additional, Boffetta, Paolo, additional, Malekzadeh, Reza, additional, and Vedanthan, Rajesh, additional

Published
2022
Full Text
View/download PDF

38. Responsiveness of PROMIS® Global Health Short Form in Outpatients with Systemic Lupus Erythematosus

Author

Kasturi, Shanthini, Szymonifka, Jackie, Berman, Jessica R., Kirou, Kyriakos A., Levine, Alana B., Sammaritano, Lisa R., and Mandl, Lisa A.

Subjects
Adult, Male, Health Status, Middle Aged, Article, Young Adult, Mental Health, Surveys and Questionnaires, Outpatients, Quality of Life, Humans, Lupus Erythematosus, Systemic, Female, Patient Reported Outcome Measures, Self Report, skin and connective tissue diseases, Aged
Abstract

To evaluate the longitudinal responsiveness (sensitivity to change) of the Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Short Form (PROMIS10) in outpatients with systemic lupus erythematosus (SLE).Outpatients with SLE who were receiving care at an academic medical center completed the PROMIS10 at 2 visits that were a minimum of 1 month apart. Responsiveness of the PROMIS10 global physical and mental health domains to Patient-Reported improvement or deterioration of health status was evaluated, as measured by standard validated instruments. Effect sizes of changes in PROMIS10 scores between visits were evaluated using Kruskal-Wallis testing.A total of 223 SLE patients enrolled and completed baseline surveys, with 186 (83.4%) completing a second set of questionnaires. The PROMIS10 demonstrated mild-to-moderate responsiveness to Patient-Reported improvement (effect size 0.29) and worsening (effect sizes -0.27 and -0.54) of health status for both global physical health and global mental health. Changes in the PROMIS10 correlated poorly with changes in physician-reported measures of disease activity.The PROMIS10 showed responsiveness over time to Patient-Reported changes in SLE health status, but not physician-assessed changes. These data suggest that the PROMIS10 can be used to efficiently measure and monitor important aspects of the SLE patient experience that are not captured by standard physician-derived metrics. Further studies are needed to evaluate the role of the PROMIS10 in optimizing longitudinal disease management in SLE and to determine its responsiveness in other chronic health conditions.

Published
2020

40. Hospital readmission in systemic sclerosis associated pulmonary hypertension: Results from the PHAROS registry.

Author

Showalter, Kimberly, Pinheiro, Laura C, Jannat-Khah, Deanna, Sobol, Irina, Szymonifka, Jackie, Finik, Jackie, Steen, Virginia D, and Gordon, Jessica K

Subjects
PULMONARY hypertension treatment, REPORTING of diseases, KRUSKAL-Wallis Test, CONFIDENCE intervals, PULMONARY hypertension, HOME care services, SYSTEMIC scleroderma, PATIENT readmissions, FISHER exact test, MANN Whitney U Test, RISK assessment, SEVERITY of illness index, COMPARATIVE studies, DESCRIPTIVE statistics, OXYGEN therapy, LOGISTIC regression analysis, ODDS ratio, DISEASE complications
Abstract

Objective To identify individual-level factors associated with hospital readmission among individuals with SSc-associated pulmonary hypertension (SSc-PH). Methods Individuals enrolled in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) registry contributed clinical data related to SSc-PH disease severity and hospital admissions. Readmission was defined as a subsequent hospitalization within 12 months of any hospital discharge. Characteristics were compared between individuals with and without readmissions using Fisher's exact test, Wilcoxon rank-sum test, or Kruskal–Wallis test. Logistic regression was used to estimate associations between clinical predictors and likelihood of readmission. Results Of 572 individuals with SSc-PH enrolled in PHAROS, 54% had ≥1 hospitalizations between 2005 and 2016. Among individuals ever-hospitalized, 34% had ≥1 readmission. Individuals with vs without readmissions had shorter median (IQR) time between index hospitalization date and next PHAROS visit [37 (3, 80) vs 81 (42, 136) days, P <0.001]. Index admissions related to PH or SSc (vs non-PH/SSc related) were associated with an increased odds of 12-month readmission [aOR 6.6 (95% CI 3.2, 13.6) and aOR 2.2 (95% CI 1.1, 4.5), respectively]. Readmission was less likely among home oxygen users (vs non-users) (aOR 0.44; 95% CI 0.22, 0.89). Race, age, sex, disease duration and disease subtype were not associated with readmission. Conclusion The strongest predictor for 12-month readmission was an index hospitalization reason related to PH. Home oxygen use was associated with lower odds of readmission. Future studies should determine whether testing for the need for home oxygen mediates the risk of readmission in SSc-PH. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

42. General Assembly, Diagnosis, Laboratory Test: Proceedings of International Consensus on Orthopedic Infections

Author

Barrack, Robert, Bhimani, Samrath, Blevins, Jason L., Blevins, Kier, Demetres, Michelle, Figgie, Mark, Fillingham, Yale, Goodman, Susan, Huddleston, James, Kahlenberg, Cynthia, Lautenbach, Charles, Lin, Jianhao, Lonner, Jess, Lynch, Maureen, Malkani, Arthur, Martin, Lily, Mirza, Serene, Rahim Najjad, Muhammad Kazim, Penna, Sreeram, Richardson, Shawn, Sculco, Peter, Shahi, AliSina, Szymonifka, Jackie, and Wang, Qiaojie

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results